AdAlta (1AD) AGM 2025 Presentation summary

Opening remarks and agenda

• CEO and Managing Director Tim Oldham presented the AGM, focusing on commercialising cellular immunotherapies and the "East to West" strategy.

Financial performance review

• Improved balance sheet and capital structure by reducing burn rate and raising $2.9 million.

• Completed obligations under NLSC and Meurs investment agreements.

Strategic initiatives and plans

• Committed to the "East to West" cellular immunotherapy strategy, with AdCella as a key growth driver.

• First product licensing agreement finalization and initial financing pending; multiple investors engaged for AdCella.

• Plans to fully launch AdCella, with potential first CAR-T in-licensing agreement in the next 3 months and additional clinical data in 9-12 months.

• Evaluating options to advance AD-214 (fibrosis) and WD-34 (malaria) via partnerships and non-dilutive funding.

• Clear growth targets: three assets secured by mid-2026, one asset into clinical trials each year from 2027.